Registry series
The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Lung and Heart-Lung Transplantation Report—2011

https://doi.org/10.1016/j.healun.2011.08.011Get rights and content

Section snippets

Statistical methods

Descriptive characteristics were used as appropriate, presenting proportions and medians ± standard deviations or 5th–95th percentiles. Survival rates were calculated by the Kaplan-Meier method and compared with the log-rank test. No adjustments were made for multiple comparisons; whenever the remaining recipient number was < 10, survival graphs were truncated. More detailed explanations of the statistical methodology accompany slides, where appropriate; slides are available online (//www.ishlt.org/registries

Volume, indications, and donor characteristics

The number of transplant centers reporting pediatric lung transplant procedures in 2009 increased to 49, compared with 40 in 2008. During the last 5 years, the number of centers reporting pediatric lung transplant procedures increased by 36%, which is likely a partial result of the retrospective data described above (Figure 1). As in previous years, most of the centers (84%) performed fewer than 5 transplant procedures annually; however, for the first time, 3 centers reported 10 to 19 pediatric

Lung retransplantation

In the interval from January 1994 to June 2010, 105 retransplant procedures were reported to the ISHLT Registry. Retransplantation was performed for obliterative bronchiolitis (OB) in 50 patients and for indications other than OB in 51. Most of the retransplantations occurred in recipients aged ≥ 12 years. In recipients with OB, 36 of 50 procedures (72%) were performed in recipients aged ≥ 12 years. Retransplantations for indications other than OB were performed in recipients aged ≥12 years in

Disclosure statement

All relevant disclosures for the Registry Director, Executive Committee Members, and authors are on file with the ISHLT and can be made available for review by contacting the Executive Director of the ISHLT. All of the figures and tables from this report, and a more comprehensive set of Registry slides are available at www.ishlt.org/registries/.

First page preview

First page preview
Click to open first page preview

References (3)

There are more references available in the full text version of this article.

Cited by (42)

  • Anesthetic Management of Transfemoral Transcatheter Aortic Valve Replacement (TAVR) in a Heart Transplant Recipient With Severely Depressed Left Ventricular Function and Renal Failure

    2017, Journal of Cardiothoracic and Vascular Anesthesia
    Citation Excerpt :

    The current recipient median life span is two decades or more. Because of improvement in surgical and medical management, this subset of patients now live long enough to present subsequent surgical and anesthetic challenges related to their aging transplanted heart, pathophysiology, and ongoing immunosuppressant treatment.1,2,11 TAVR is a treatment option for inoperable and prohibitively high-risk surgical patients.

  • Alternative tacrolimus and sirolimus regimen associated with rapid resolution of posterior reversible encephalopathy syndrome after lung transplantation

    2014, Pediatric Neurology
    Citation Excerpt :

    Maintenance immunosuppression after lung transplantation typically includes a three-drug combination with a calcineurin inhibitor, an antimetabolite, and a systemic corticosteroid.1-3

  • Managing end stage lung disease in children

    2014, Paediatric Respiratory Reviews
  • Body mass index and its effect on outcome in children after lung transplantation

    2013, Journal of Heart and Lung Transplantation
    Citation Excerpt :

    Most of the children in the Registry undergo lung transplantation due to advanced CF lung disease, and this has not changed during the last 2 decades.4 In particular,>66% of pediatric lung transplant recipients in Europe have CF; and even in North America, CF is present in>54% of children requiring a lung transplant procedure.4 Malnutrition is common in CF patients, and several factors contribute to this, including malabsorption, chronic inflammation, increased energy expenditure, and chronic CF-related sinus disease.12

View all citing articles on Scopus
View full text